SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Amber Dahlin, Matthias Wittwer, Melanie de la Cruz, Jonathan M. Woo, Rujuta Bam, Valeska Scharen-Guivel, John Flaherty, Adrian S. Ray, Tomas Cihlar, Samir K. Gupta, Kathleen M. Giacomini, A pharmacogenetic candidate gene study of tenofovir-associated Fanconi syndrome, Pharmacogenetics and Genomics, 2015, 25, 2, 82

    CrossRef

  2. 2
    Hemalatha Ramamoorthy, Premila Abraham, Bina Isaac, Mitochondrial Dysfunction and Electron Transport Chain Complex Defect in a Rat Model of Tenofovir Disoproxil Fumarate Nephrotoxicity, Journal of Biochemical and Molecular Toxicology, 2014, 28, 6
  3. 3
    Albert Mwafongo, Kondwani Nkanaunena, Yu Zheng, Evelyn Hogg, Wadzanai Samaneka, Lloyd Mulenga, Abraham Siika, Judith Currier, Shahin Lockman, Michael D. Hughes, Mina Hosseinipour, Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine, AIDS, 2014, 1

    CrossRef

  4. 4
    Lai Wei, Shanlian Hu, Jinlin Hou, Gordon Liu, Hong Ren, Zhongping Duan, Qing Xie, Xiao Fang, Jidong Jia, A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China, Value in Health Regional Issues, 2013, 2, 1, 48

    CrossRef

  5. 5
    Premila Abraham, Hemalatha Ramamoorthy, Bina Isaac, Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate - induced mitochondrial damage and increased oxido-nitrosative stress in the kidney, Journal of Biomedical Science, 2013, 20, 1, 61

    CrossRef

  6. 6
    Z. Han, Y. Shi, J. Zhu, Y. Chen, F. Yin, L. Xia, G. Luo, Z. Gao, J. Liu, G. Jia, C. Li, X. Zhou, Y. Han, Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis, Journal of Viral Hepatitis, 2013, 20,
  7. 7
    Adikwu Elias, Ogbuehi Ijeoma, Nkereuwem Jonathan Edikpo, Deo Oputiri, Oru-Bo Precious Geoffrey, Tenofovir Renal Toxicity: Evaluation of Cohorts and Clinical Studies—Part One, Pharmacology & Pharmacy, 2013, 04, 09, 651

    CrossRef

  8. 8
    Murli Purswani, Kunjal Patel, Jeffrey B. Kopp, George R. Seage, Miriam C. Chernoff, Rohan Hazra, George K. Siberry, Lynne M. Mofenson, Gwendolyn B. Scott, Russell B. Van Dyke, Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection, The Pediatric Infectious Disease Journal, 2013, 32, 5, 495

    CrossRef

  9. 9
    Ikwo Oboho, Alison G. Abraham, Lorie Benning, Kathryn Anastos, Anjali Sharma, Mary Young, Pamela Burian, Monica Gandhi, Mardge Cohen, Lynda Szczech, Tenofovir Use and Urinary Biomarkers Among HIV-Infected Women in the Womenʼs Interagency HIV Study (WIHS), JAIDS Journal of Acquired Immune Deficiency Syndromes, 2013, 62, 4, 388

    CrossRef

  10. 10
    Lene Ryom, Amanda Mocroft, Jens Lundgren, HIV Therapies and the Kidney: Some Good, Some Not So Good?, Current HIV/AIDS Reports, 2012, 9, 2, 111

    CrossRef

  11. 11
    Robert C. Kalayjian, Bryan Lau, Rhoderick N. Mechekano, Heidi M. Crane, Benigno Rodriguez, Robert A. Salata, Zipporah Krishnasami, James H. Willig, Jeffrey N. Martin, Richard D. Moore, Joseph J. Eron, Mari M. Kitahata, Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care, AIDS, 2012, 26, 15, 1907

    CrossRef

  12. 12
    Robert G. Gish, Margaret D. Clark, Steve D. Kane, Richard E. Shaw, Michael F. Mangahas, Sumbella Baqai, Similar Risk of Renal Events Among Patients Treated With Tenofovir or Entecavir for Chronic Hepatitis B, Clinical Gastroenterology and Hepatology, 2012, 10, 8, 941

    CrossRef

  13. 13
    Andy I Choi, Eric Vittinghoff, Steven G Deeks, Cristin C Weekley, Yongmei Li, Michael G Shlipak, Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons, AIDS, 2011, 25, 10, 1289

    CrossRef

  14. 14
    Mark Mirochnick, Brookie M. Best, Diana F. Clarke, Antiretroviral Pharmacology: Special Issues Regarding Pregnant Women and Neonates, Clinics in Perinatology, 2010, 37, 4, 907

    CrossRef

  15. 15
    Amanda Mocroft, Ole Kirk, Peter Reiss, Stephane De Wit, Dalibor Sedlacek, Marek Beniowski, Jose Gatell, Andrew N Phillips, Bruno Ledergerber, Jens D Lundgren, Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, 2010, 24, 11, 1667

    CrossRef

  16. 16
    Michael Horberg, Beth Tang, William Towner, Michael Silverberg, Susan Bersoff-Matcha, Leo Hurley, Joseph Chang, Jackie Blank, Charles Quesenberry, Daniel Klein, Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, 2010, 53, 1, 62

    CrossRef

  17. 17
    David Cooper, Gail Matthews, Kucers' The Use of Antibiotics Sixth Edition, 2010,

    CrossRef

  18. 18
    Jérôme Tourret, Isabelle Tostivint, Gilbert Deray, Corinne Isnard-Bagnis, Néphropathies rencontrées au cours de l’infection par le virus de l’immunodéficience humaine (VIH), Néphrologie & Thérapeutique, 2009, 5, 6, 576

    CrossRef

  19. 19
    Benjamin Young, Kate Buchacz, Anne Moorman, Kathy C. Wood, John T. Brooks, Renal Function in Patients with Preexisting Renal Disease Receiving Tenofovir-Containing Highly Active Antiretroviral Therapy in the HIV Outpatient Study, AIDS Patient Care and STDs, 2009, 23, 8, 589

    CrossRef

  20. 20
    Alice M. Jenh, Chloe L. Thio, Paul A. Pham, Tenofovir for the Treatment of Hepatitis B Virus, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009, 29, 10
  21. 21
    Sarah M. Wood, Samir S. Shah, Andrew P. Steenhoff, Kevin E.C. Meyers, Bernard S. Kaplan, Richard M. Rutstein, Tenofovir-Associated Nephrotoxicity in Two HIV-Infected Adolescent Males, AIDS Patient Care and STDs, 2009, 23, 1, 1

    CrossRef

  22. 22
    Mohamed G. Atta, Gilbert Deray, Gregory M. Lucas, Antiretroviral Nephrotoxicities, Seminars in Nephrology, 2008, 28, 6, 563

    CrossRef

  23. 23
    G. Guaraldi, A. Roverato, C. Giovanardi, F. Ravera, N. Squillace, G. Orlando, G. Cappelli, R. Esposito, F. Palella, Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study, Journal of Antimicrobial Chemotherapy, 2008, 63, 2, 374

    CrossRef

  24. 24
    Marianne Harris, Nephrotoxicity associated with antiretroviral therapy in HIV-infected patients, Expert Opinion on Drug Safety, 2008, 7, 4, 389

    CrossRef

  25. 25
    F. Jiménez Zorzo, C. Beltrán Audera, C. Bruscas Izu, Osteomalacia hipofosfatémica en un paciente infectado por VIH en tratamiento con tenofovir, Revista Española de Enfermedades Metabólicas Óseas, 2008, 17, 2, 22

    CrossRef

  26. 26
    Alexandre B Libório, Lúcia Andrade, Leonardo V B Pereira, Talita R C Sanches, Maria H Shimizu, Antonio C Seguro, Rosiglitazone reverses tenofovir-induced nephrotoxicity, Kidney International, 2008, 74, 7, 910

    CrossRef

  27. 27
    Giordano Madeddu, Paolo Bonfanti, Giuseppe V. De Socio, Silvia Carradori, Carmela Grosso, Patrizia Marconi, Giovanni Penco, Elena Rosella, Sebastiano Miccolis, Sara Melzi, Maria Stella Mura, Simona Landonio, Elena Ricci, Tiziana Quirino, for the CISAI Group, Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project, Biomedicine & Pharmacotherapy, 2008, 62, 1, 6

    CrossRef

  28. 28
    Heidi M Crane, Bryan Kestenbaum, Robert D Harrington, Mari M Kitahata, Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir, AIDS, 2007, 21, 11, 1431

    CrossRef

  29. 29
    Amanda Mocroft, Ole Kirk, Jose Gatell, Peter Reiss, Panagiotis Gargalianos, Kai Zilmer, Marek Beniowski, Jean-Paul Viard, Schlomo Staszewski, Jens D Lundgren, Chronic renal failure among HIV-1-infected patients, AIDS, 2007, 21, 9, 1119

    CrossRef

  30. 30
    David J Quan, Marion G Peters, Tenofovir disoproxil fumarate for the treatment of hepatitis B virus infection: pharmacokinetics and clinical efficacy, Therapy, 2007, 4, 2, 141

    CrossRef

  31. 31
    Michael D Gitman, David Hirschwerk, Cindy H Baskin, Pravin C Singhal, Tenofovir-induced kidney injury, Expert Opinion on Drug Safety, 2007, 6, 2, 155

    CrossRef

  32. 32
    Mark R Nelson, Christine Katlama, Julio S Montaner, David A Cooper, Brian Gazzard, Bonaventura Clotet, Adriano Lazzarin, Knud Schewe, Joep Lange, Christina Wyatt, Sue Curtis, Shan-Shan Chen, Stephen Smith, Norbert Bischofberger, James F Rooney, The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years, AIDS, 2007, 21, 10, 1273

    CrossRef

  33. 33
    Christina M Wyatt, Paul E Klotman, Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection, Expert Opinion on Drug Safety, 2006, 5, 2, 275

    CrossRef

  34. 34
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2006, 15, 2
  35. 35
    K Buchacz, JT Brooks, T Tong, AC Moorman, RK Baker, SD Holmberg, A Greenberg, Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy, HIV Medicine, 2006, 7, 7
  36. 36
    J. Roling, H. Schmid, M. Fischereder, R. Draenert, F. D. Goebel, HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy--Induced Nephropathy, Clinical Infectious Diseases, 2006, 42, 10, 1488

    CrossRef

  37. 37
    Paul A Pham, Joel E Gallant, Tenofovir disoproxil fumarate for the treatment of HIV infection, Expert Opinion on Drug Metabolism & Toxicology, 2006, 2, 3, 459

    CrossRef

  38. 38
    Stephen N. Wong, Anna S.F. Lok, Tenofovir disoproxil fumarate: Role in hepatitis B treatment, Hepatology, 2006, 44, 2
  39. 39
    Florian van Bömmel, Bernhard Zöllner, Christoph Sarrazin, Ulrich Spengler, Dietrich Hüppe, Bernd Möller, Heinz-Hubert Feucht, Bertram Wiedenmann, Thomas Berg, Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy, Hepatology, 2006, 44, 2
  40. 40
    Brian G Gazzard, Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients, Expert Opinion on Pharmacotherapy, 2006, 7, 6, 793

    CrossRef

  41. 41
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,